Currently out of the existing stock ratings of Michael Schmidt, 247 are a BUY (84.3%), 46 are a HOLD (15.7%).

Michael Schmidt

Work Performance Price Targets & Ratings Chart

Analyst Michael Schmidt, currently employed at GUGGENHEIM, carries an average stock price target met ratio of 53.79% that have a potential upside of 38.81% achieved within 318 days.

Michael Schmidt’s has documented 540 price targets and ratings displayed on 60 stocks. The coverage is on Healthcare, Technology, Consumer Defensive sectors.

Most recent stock forecast was given on TNGX, Tango Therapeutics at 12-Aug-2026.

Wall Street Analyst Michael Schmidt

Analyst best performing recommendations are on ZNTL (ZENTALIS PHARMACEUTICALS LLC).
The best stock recommendation documented was for ZNTL (ZENTALIS PHARMACEUTICALS LLC) at 3/27/2026. The price target of $6 was fulfilled within 14 days with a profit of $3.9 (185.71%) receiving and performance score of 132.65.

Average potential price target upside

of $264.53 (30.68%) on BLUE (BLUEBIRD BIO).
of $99.08 (65.32%) on ACET (ADICET BIO).
of $43.16 (75.97%) on RVMD (REVOLUTION MEDICINES).

CLVS Clovis Oncology EXEL Exelixis FPRX Five Prime Therapeutics IMMU Immunomedics IMRX Immuneering Corp MRTX Mirati Ther RLAY Relay Therapeutics AGIO Agios Pharm BLUE Bluebird bio BPMC Blueprint Medicines Corp DRNA Dicerna Pharmaceuticals IMGN ImmunoGen INCY yte FATE Fate Therapeutics GMAB Genmab AS IONS Ionis Pharmaceuticals ORIC Oric Pharmaceuticals PBYI Puma Biotechnology RAIN Rain Therapeutics ACET Adicet Bio RUBY Rubius Therapeutics TPTX Turning Point Therapeutics XNCR Xencor SGEN Seagen ALKS Alkermes Plc ALNY Alnylam Pharmaceuticals ZNTL Zentalis Pharmaceuticals Llc BGNE BeiGene Ltd DCPH Deciphera Pharmaceuticals LLC AFMD Affimed NV ALLO Allogene Therapeutics ARVN Arvinas ERAS Erasca NLTX Neoleukin Therapeutics NTLA Intellia Therapeutics RVMD Revolution Medicines ADAP Adaptimmune Therapeutics Plc MRSN Mersana Therapeutics SNDX Syndax Pharmaceuticals QURE Uniqure NV IMCR Immunocore Holdings Ltd ADCT ADC Therapeutics SA KYMR Kymera Therapeutics MRUS Merus BV SWTX SpringWorks Therapeutics VSTM Verastem BOLT Bolt Biotherapeutics ABUS Arbutus Biopharma Corp ARRY Array Technologies CMPX Compass Therapeutics IMNM Immunome SYBX Synlogic NBTX GLUE Monte Rosa Therapeutics TNGX Tango Therapeutics AVBP ArriVent BioPharma, Common Stock BG Bunge CTMX CytomX Therapeutics SG Sweetgreen TRIL Trillium Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Edward White (HC WAINWRIGHT)